nodes	percent_of_prediction	percent_of_DWPC	metapath
Nafarelin—Hypovolaemia—Furosemide—dilated cardiomyopathy	0.0713	0.0715	CcSEcCtD
Nafarelin—Breast enlargement—Spironolactone—dilated cardiomyopathy	0.0627	0.0628	CcSEcCtD
Nafarelin—Breast pain—Spironolactone—dilated cardiomyopathy	0.0466	0.0467	CcSEcCtD
Nafarelin—Gynaecomastia—Spironolactone—dilated cardiomyopathy	0.0364	0.0364	CcSEcCtD
Nafarelin—Transient ischaemic attack—Lisinopril—dilated cardiomyopathy	0.0329	0.0329	CcSEcCtD
Nafarelin—Gastritis—Spironolactone—dilated cardiomyopathy	0.0261	0.0262	CcSEcCtD
Nafarelin—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.0217	0.0217	CcSEcCtD
Nafarelin—Bladder pain—Furosemide—dilated cardiomyopathy	0.02	0.02	CcSEcCtD
Nafarelin—Breast pain—Lisinopril—dilated cardiomyopathy	0.019	0.0191	CcSEcCtD
Nafarelin—Alopecia—Spironolactone—dilated cardiomyopathy	0.018	0.0181	CcSEcCtD
Nafarelin—Oliguria—Lisinopril—dilated cardiomyopathy	0.018	0.018	CcSEcCtD
Nafarelin—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.0166	0.0166	CcSEcCtD
Nafarelin—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.0162	0.0162	CcSEcCtD
Nafarelin—Cystitis—Lisinopril—dilated cardiomyopathy	0.016	0.0161	CcSEcCtD
Nafarelin—Bladder pain—Lisinopril—dilated cardiomyopathy	0.015	0.015	CcSEcCtD
Nafarelin—Muscular weakness—Furosemide—dilated cardiomyopathy	0.0142	0.0142	CcSEcCtD
Nafarelin—Abdominal distension—Furosemide—dilated cardiomyopathy	0.014	0.014	CcSEcCtD
Nafarelin—Hepatic function abnormal—Lisinopril—dilated cardiomyopathy	0.0138	0.0138	CcSEcCtD
Nafarelin—Libido decreased—Lisinopril—dilated cardiomyopathy	0.013	0.013	CcSEcCtD
Nafarelin—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.0123	0.0123	CcSEcCtD
Nafarelin—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.0119	0.012	CcSEcCtD
Nafarelin—Urticaria—Spironolactone—dilated cardiomyopathy	0.0115	0.0115	CcSEcCtD
Nafarelin—Gastritis—Lisinopril—dilated cardiomyopathy	0.0107	0.0107	CcSEcCtD
Nafarelin—Pruritus—Spironolactone—dilated cardiomyopathy	0.0103	0.0103	CcSEcCtD
Nafarelin—Sweating increased—Lisinopril—dilated cardiomyopathy	0.0101	0.0102	CcSEcCtD
Nafarelin—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00992	0.00994	CcSEcCtD
Nafarelin—Dysuria—Lisinopril—dilated cardiomyopathy	0.00973	0.00976	CcSEcCtD
Nafarelin—Malnutrition—Furosemide—dilated cardiomyopathy	0.00967	0.00969	CcSEcCtD
Nafarelin—Dizziness—Spironolactone—dilated cardiomyopathy	0.00959	0.00961	CcSEcCtD
Nafarelin—Weight increased—Lisinopril—dilated cardiomyopathy	0.00947	0.00949	CcSEcCtD
Nafarelin—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00947	0.00949	CcSEcCtD
Nafarelin—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00942	0.00944	CcSEcCtD
Nafarelin—Depression—Lisinopril—dilated cardiomyopathy	0.00925	0.00927	CcSEcCtD
Nafarelin—Vomiting—Spironolactone—dilated cardiomyopathy	0.00922	0.00924	CcSEcCtD
Nafarelin—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00915	0.00917	CcSEcCtD
Nafarelin—Rash—Spironolactone—dilated cardiomyopathy	0.00914	0.00916	CcSEcCtD
Nafarelin—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00913	0.00915	CcSEcCtD
Nafarelin—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.0091	0.00912	CcSEcCtD
Nafarelin—Headache—Spironolactone—dilated cardiomyopathy	0.00908	0.0091	CcSEcCtD
Nafarelin—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00875	0.00877	CcSEcCtD
Nafarelin—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00871	0.00873	CcSEcCtD
Nafarelin—Vertigo—Furosemide—dilated cardiomyopathy	0.00868	0.0087	CcSEcCtD
Nafarelin—Nausea—Spironolactone—dilated cardiomyopathy	0.00861	0.00863	CcSEcCtD
Nafarelin—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00835	0.00837	CcSEcCtD
Nafarelin—Shock—Furosemide—dilated cardiomyopathy	0.00776	0.00778	CcSEcCtD
Nafarelin—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00763	0.00764	CcSEcCtD
Nafarelin—Anorexia—Furosemide—dilated cardiomyopathy	0.00752	0.00754	CcSEcCtD
Nafarelin—Alopecia—Lisinopril—dilated cardiomyopathy	0.00736	0.00738	CcSEcCtD
Nafarelin—Mental disorder—Lisinopril—dilated cardiomyopathy	0.0073	0.00732	CcSEcCtD
Nafarelin—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00725	0.00727	CcSEcCtD
Nafarelin—Tension—Lisinopril—dilated cardiomyopathy	0.00712	0.00713	CcSEcCtD
Nafarelin—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.0071	0.00712	CcSEcCtD
Nafarelin—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00708	0.0071	CcSEcCtD
Nafarelin—Nervousness—Lisinopril—dilated cardiomyopathy	0.00704	0.00706	CcSEcCtD
Nafarelin—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00686	0.00687	CcSEcCtD
Nafarelin—Constipation—Furosemide—dilated cardiomyopathy	0.00675	0.00676	CcSEcCtD
Nafarelin—Vertigo—Lisinopril—dilated cardiomyopathy	0.00652	0.00653	CcSEcCtD
Nafarelin—Palpitations—Lisinopril—dilated cardiomyopathy	0.00641	0.00642	CcSEcCtD
Nafarelin—Urticaria—Furosemide—dilated cardiomyopathy	0.00627	0.00628	CcSEcCtD
Nafarelin—Chest pain—Lisinopril—dilated cardiomyopathy	0.00617	0.00619	CcSEcCtD
Nafarelin—Myalgia—Lisinopril—dilated cardiomyopathy	0.00617	0.00619	CcSEcCtD
Nafarelin—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00617	0.00619	CcSEcCtD
Nafarelin—Oedema—Lisinopril—dilated cardiomyopathy	0.00592	0.00593	CcSEcCtD
Nafarelin—Shock—Lisinopril—dilated cardiomyopathy	0.00582	0.00584	CcSEcCtD
Nafarelin—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00572	0.00574	CcSEcCtD
Nafarelin—Asthenia—Furosemide—dilated cardiomyopathy	0.00566	0.00567	CcSEcCtD
Nafarelin—Anorexia—Lisinopril—dilated cardiomyopathy	0.00564	0.00565	CcSEcCtD
Nafarelin—Pruritus—Furosemide—dilated cardiomyopathy	0.00558	0.00559	CcSEcCtD
Nafarelin—Diarrhoea—Furosemide—dilated cardiomyopathy	0.0054	0.00541	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00539	0.0054	CcSEcCtD
Nafarelin—Insomnia—Lisinopril—dilated cardiomyopathy	0.00535	0.00537	CcSEcCtD
Nafarelin—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00532	0.00533	CcSEcCtD
Nafarelin—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00528	0.00529	CcSEcCtD
Nafarelin—Dizziness—Furosemide—dilated cardiomyopathy	0.00522	0.00523	CcSEcCtD
Nafarelin—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00515	0.00516	CcSEcCtD
Nafarelin—Constipation—Lisinopril—dilated cardiomyopathy	0.00506	0.00507	CcSEcCtD
Nafarelin—Vomiting—Furosemide—dilated cardiomyopathy	0.00502	0.00503	CcSEcCtD
Nafarelin—Rash—Furosemide—dilated cardiomyopathy	0.00497	0.00499	CcSEcCtD
Nafarelin—Dermatitis—Furosemide—dilated cardiomyopathy	0.00497	0.00498	CcSEcCtD
Nafarelin—Headache—Furosemide—dilated cardiomyopathy	0.00494	0.00495	CcSEcCtD
Nafarelin—Urticaria—Lisinopril—dilated cardiomyopathy	0.0047	0.00471	CcSEcCtD
Nafarelin—Nausea—Furosemide—dilated cardiomyopathy	0.00469	0.0047	CcSEcCtD
Nafarelin—Asthenia—Lisinopril—dilated cardiomyopathy	0.00425	0.00426	CcSEcCtD
Nafarelin—Pruritus—Lisinopril—dilated cardiomyopathy	0.00419	0.0042	CcSEcCtD
Nafarelin—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00405	0.00406	CcSEcCtD
Nafarelin—Dizziness—Lisinopril—dilated cardiomyopathy	0.00391	0.00392	CcSEcCtD
Nafarelin—Vomiting—Lisinopril—dilated cardiomyopathy	0.00376	0.00377	CcSEcCtD
Nafarelin—Rash—Lisinopril—dilated cardiomyopathy	0.00373	0.00374	CcSEcCtD
Nafarelin—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00373	0.00374	CcSEcCtD
Nafarelin—Headache—Lisinopril—dilated cardiomyopathy	0.00371	0.00372	CcSEcCtD
Nafarelin—Nausea—Lisinopril—dilated cardiomyopathy	0.00352	0.00352	CcSEcCtD
Nafarelin—GNRHR—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.000199	0.0892	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.000185	0.0829	CbGpPWpGaD
Nafarelin—GNRHR—GPCRs, Other—CXCR3—dilated cardiomyopathy	0.000157	0.0703	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—AGTR1—dilated cardiomyopathy	0.000153	0.0686	CbGpPWpGaD
Nafarelin—GNRHR—GPCRs, Other—ADRB2—dilated cardiomyopathy	0.000123	0.0552	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	7.31e-05	0.0327	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	6.53e-05	0.0292	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	6.29e-05	0.0281	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	6.29e-05	0.0281	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	5.85e-05	0.0262	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	5.66e-05	0.0253	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—AGT—dilated cardiomyopathy	5.14e-05	0.023	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	4.84e-05	0.0216	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—AGTR2—dilated cardiomyopathy	4.79e-05	0.0214	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCL2—dilated cardiomyopathy	4.79e-05	0.0214	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	4.6e-05	0.0206	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	4.59e-05	0.0205	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCR3—dilated cardiomyopathy	4.45e-05	0.0199	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—ADRB1—dilated cardiomyopathy	4.31e-05	0.0193	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—AGTR1—dilated cardiomyopathy	3.68e-05	0.0165	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—ADRB2—dilated cardiomyopathy	3.5e-05	0.0156	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	3.4e-05	0.0152	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	3.19e-05	0.0143	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	2.71e-05	0.0121	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	2.71e-05	0.0121	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—AGT—dilated cardiomyopathy	2.59e-05	0.0116	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	2.52e-05	0.0113	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—AGTR2—dilated cardiomyopathy	2.46e-05	0.011	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CXCL2—dilated cardiomyopathy	2.46e-05	0.011	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	2.44e-05	0.0109	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CXCR3—dilated cardiomyopathy	2.29e-05	0.0102	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—ADRB1—dilated cardiomyopathy	2.21e-05	0.0099	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	2.19e-05	0.00979	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	2.08e-05	0.00931	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	1.98e-05	0.00884	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—AGTR1—dilated cardiomyopathy	1.89e-05	0.00846	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—ADRB2—dilated cardiomyopathy	1.79e-05	0.00802	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.64e-05	0.00732	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—RAC1—dilated cardiomyopathy	1.53e-05	0.00686	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—AGT—dilated cardiomyopathy	1.47e-05	0.00655	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.45e-05	0.0065	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.45e-05	0.0065	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—RAC1—dilated cardiomyopathy	1.39e-05	0.00623	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.35e-05	0.00604	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—AGT—dilated cardiomyopathy	1.33e-05	0.00595	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.31e-05	0.00585	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.12e-05	0.005	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.06e-05	0.00474	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.23e-06	0.00413	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.1e-06	0.00407	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RAC1—dilated cardiomyopathy	8.23e-06	0.00368	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AGT—dilated cardiomyopathy	7.86e-06	0.00352	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.33e-06	0.00283	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RAF1—dilated cardiomyopathy	5.45e-06	0.00244	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EGFR—dilated cardiomyopathy	3.74e-06	0.00167	CbGpPWpGaD
